Pravastatin reduces all-cause mortality in elderly individuals at risk of liver fibrosis: Post hoc analysis of the PROSPER trial
The progressive stages of MASLD (liver fibrosis) are associated with liver-related and CV complications in middle-aged cohorts (∼55 years of age). The impact of liver fibrosis in elderly populations is less well studied. In addition, the use of statins has long been debated, but evidence appears to point to a beneficial effect in populations with MASLD. However, data from prospective trials remain limited. Our findings indicate a potential survival benefit associated with pravastatin use in the elderly (>70 years of age) with an indication of liver fibrosis.
Authors
- J. Wouter Jukema (ORCID: https://orcid.org/0000-0002-3246-8359)
- Vivian de Jong (ORCID: https://orcid.org/0000-0002-4692-479X)
- Willy Theel (ORCID: https://orcid.org/0000-0003-3639-0963)
- Stella Trompet (ORCID: https://orcid.org/0000-0001-5006-0528)
- Manuel Castro Cabezas (ORCID: https://orcid.org/0009-0009-5164-2082)
- Diederick E. Grobbee
Institutions
- Leiden University (NL)
- Leiden University Medical Center (NL)
- Erasmus MC (NL)
- University Medical Center Utrecht (NL)
- Sint Franciscus Gasthuis (NL)
- Netherlands Heart Institute (NL)
- Yulius (NL)
Publication Details
- Journal
- JHEP Reports
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1016/j.jhepr.2025.101337
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Bristol-Myers Squibb